Abstract
We examined whether prophylactically administered anti-respiratory syncytial virus (anti-RSV) G monoclonal antibody (MAb) would decrease the pulmonary inflammation associated with primary RSV infection and formalin-inactivated RSV (FI-RSV)-enhanced disease in mice. MAb 131-2G administration 1 day prior to primary infection reduced the pulmonary inflammatory response and the level of RSV replication. Further, intact or F(ab')(2) forms of MAb 131-2G administered 1 day prior to infection in FI-RSV-vaccinated mice reduced enhanced inflammation and disease. This study shows that an anti-RSV G protein MAb might provide prophylaxis against both primary infection and FI-RSV-associated enhanced disease. It is possible that antibodies with similar reactivities might prevent enhanced disease and improve the safety of nonlive virus vaccines.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
-
Research Support, U.S. Gov't, Non-P.H.S.
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Animals
-
Antibodies, Monoclonal / immunology
-
Antibodies, Monoclonal / therapeutic use*
-
Antibodies, Viral / immunology
-
Antibodies, Viral / therapeutic use*
-
Body Weight
-
Bronchoalveolar Lavage Fluid / chemistry
-
Bronchoalveolar Lavage Fluid / cytology
-
Chemoprevention / methods*
-
Mice
-
Mice, Inbred BALB C
-
Pneumonia / immunology
-
Pneumonia / pathology
-
Pneumonia / prevention & control*
-
Respiratory Syncytial Virus Infections / immunology
-
Respiratory Syncytial Virus Infections / pathology
-
Respiratory Syncytial Virus Infections / prevention & control*
-
Respiratory Syncytial Virus Vaccines / immunology*
-
Respiratory Syncytial Viruses / immunology
-
Respiratory Syncytial Viruses / pathogenicity
-
Vaccines, Inactivated / immunology
-
Viral Fusion Proteins / immunology*
-
Viral Load
Substances
-
Antibodies, Monoclonal
-
Antibodies, Viral
-
G glycoprotein, Respiratory syncytial virus
-
Respiratory Syncytial Virus Vaccines
-
Vaccines, Inactivated
-
Viral Fusion Proteins